drugset / Trial / NCT06657703
Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective of this phase Ia study is to evaluate the safety and tolerability of single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects. Secondary objectives of study are as follows: To estimate the PK parameters of single-ascending SC doses of HC022 in healthy subjects；To evaluate the immunogenicity of HC022 administered to healthy subjects.
Timeline
- Start
- 2024-11-25
- Primary completion
- 2025-08-30
- Completion
- 2026-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HC022 | Unknown | 5 mg | Subcutaneous |
| Subject | HC022 | Unknown | 50 mg | Subcutaneous |
| Subject | HC022 | Unknown | 150 mg | Subcutaneous |
| Subject | HC022 | Unknown | 450 mg | Subcutaneous |
| Subject | HC022 | Unknown | 900 mg | Subcutaneous |